Bhatnagar

Bhavana "Tina" Bhatnagar , DO

Associate Professor, Director of Hematology & Medical Oncology

Contact

Send an Email
Phone
304-243-6442
Fax
304-243-3715
Address
Wheeling Hospital
Division of Hematology / Oncology (WVUCI)
1 Medical Park, Tower 4, Suite 300
Wheeling, WV 26003
Additions & Corrections?

Positions

Assistant Professor

Organization:
School of Medicine
Department:
Medicine
Classification:
Faculty

Associate Professor

Organization:
WVU Cancer Institute
Classification:
Faculty

Education

  • DO, Philadelphia College of Osteopathic Medicine, Philadelphia, PA, 2007

Publications

1. Bhatnagar B, Pelser C, Gilmore S, Nand T, Bao T (2013) Acupuncture and Low Dose Gabapentin Effectively Treat Paclitaxel Induced Peripheral Neuropathy and Prevent Chemotherapy Dose Reduction. Altern Integr Med. 2013 July 4; 2:126. doi:10.4172/2327-5162.1000126
 
2. Bhatnagar B, Rapoport AP, Fang H, Ilyas C, Marangoz D, Akbulut V, Ruehle K, Badros A, Yanovich S, Akpek G. Single center experience with total- body irradiation and melphalan (TBI-MEL) myeloablative conditioning regimen for allogeneic stem cell transplantation (SCT) in patients with refractory hematologic malignancies. Ann Hematol. 2014 Apr; 93(4): 653-60. Epub 2013 Oct 6. PMCID: PMC7101620.
 
3. Bhatnagar B, Duong VH, Gourdin TS, Tidwell ML, Chen C, Ning Y, Emadi A, Sausville EA, Baer MR. Ten-day decitabine as initial therapy for newly diagnosed patients with acute myeloid leukemia unfit for intensive chemotherapy. Leuk Lymphoma. 2014 Jul; 55(7): 1533-7 Epub 2014 Feb 4. PMID: 24144313.
 
4. Bhatnagar B, Gilmore S, Goloubeva O, Pelser C, Medeiros M, Chumsri S, Tkaczuk K, Edelman M, Bao T. Chemotherapy dose reduction due to chemotherapy induced peripheral neuropathy in breast cancer patients receiving chemotherapy in the neoadjuvant or adjuvant settings: a single- center experience. Springerplus. 2014 Jul 16; 3: 366. PMCID: PMC4117856.
 
5. Bhatnagar B and Garzon R. The use of molecular genetics to refine prognosis in acute myeloid leukemia: current hematologic malignancy reports. Curr Hematol Malig Rep. 2014 Jun; 9(2): 148-57. PMID: 24659319
 
6. Duong VH, Bhatnagar B, Zandberg DP, Vannorsdall EJ, Tidwell ML, Chen Q, Baer MR. Lack of objective response of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) to decitabine after failure of azacitidine. Leuk Lymphoma. 2015 Jun; 56(6): 1718-22. Epub 2014 Nov 3. PMID: 25263320.
 
7. Bhatnagar B, Blachly JS, Kohlschmidt J, Eisfeld AK, Volinia S, Nicolet D, Carroll AJ, Block AM, Kolitz JE, Stone RM, Mrózek K, Byrd JC, Bloomfield CD. Clinical features, and gene- and microRNA-expression patterns in adult acute leukemia patients with t(11;19)(q23;p13.1) and t(11;19)(q23;p13.3). Leukemia. 2015 Dec 16. PMID: 26669971.
 
8. Bhatnagar B, Eisfeld AK, Nicolet D, Mrózek K, Blachly JS, Orwick S, Lucas DM, Kohlschmidt J, Blum W, Kolitz JE, Stone RM, Bloomfield CD, Byrd JC. Persistence of DNMT3A R882 mutations during remission does not adversely affect outcomes of patients with acute myeloid leukaemia.Br J Haematol. 2016 Aug 1. PMCID: PMC5063708.
 
9. Bhatnagar B, Garzon R. Long noncoding RNAs to predict survival in acute myeloid leukemia: a step toward personalized medicine? Biomark Med. 2016 Sept 1: 10(9): 935-938. PMID: 27548737.
 
10. Bhatnagar B, Eisfeld AK, Kohlschmidt JK, Mrozek K, Nicolet D, Papaioannou D, Walker C, Orwick S, Blachly J, Kolitz J, Powell BL, Carroll A, Stone R, Byrd JC and Bloomfield CD. Clinical and molecular characterization of patients with acute myeloid leukemia and sole trisomies of chromosomes 4, 8, 11, 13 or 21. Leukemia. 2020 Feb;34(2):358-368. Epub 2019 Aug 28. PMCID: PMC6995758.
 
11. Bhatnagar B, Zhao Q, Mims AS, Vasu S, Behbehani GK, Larkin K, Blachly JS, Blum W, Klisovic RB, Ruppert AS, Orwick S, Oakes C, Ranganathan P, Byrd JC, Walker AR, Garzon R. Selinexor in combination with decitabine in patients with acute myeloid leukemia: results from a phase 1 study. Leuk Lymphoma. 2020 Feb;61(2):387-396. PMID: 31545113
 
12. Jeon JY, Zhao Q, Buelow DR, Phelps M, Walker AR, Mims AS, Vasu S, Behbehani G, Blachly J, Blum W, Klisovic RB, Byrd JC, Garzon R, Baker SD, Bhatnagar B. Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positve AML. Investigational New Drugs. 2020 Apr;38(2):340-349. doi: 10.1007/s10637-019-00786-4. Epub 2019 May 17. PMCID: PMC6858927.
 
13. Koenig KL, Sahasrabudhe KD, Sigmund AM, Bhatnagar B. AML with Myelodysplasia-Related Changes: Development, Challenges, and Treatment Advances. Genes (Basel). 2020 Jul 24;11(8):E845. PMCID: PMC7464320.
 
14. Bhatnagar B, Kohlschmidt J, Mrózek K, Zhao Q, Fisher JL, Nicolet D, Walker CJ, Mims AS, Oakes C, Giacopelli B, Orwick S, Boateng I, Blachly JS, Maharry SE, Carroll AJ, Powell BL, Kolitz JE, Stone RM, Byrd JC, Paskett ED, de la Chapelle A, Garzon R, Eisfeld AK. Poor Survival and Differential Impact of Genetic Features of Black Patients with Acute Myeloid Leukemia. Cancer Discov. 2021 Mar;11(3):626-637. Epub 2020 Dec 4. PMCID: PMC7933110
 
15. Sweet K, Bhatnagar B, Döhner H, Donnellan W, Frankfurt O, Heuser M, Kota V, Liu H, Raffoux E, Roboz GJ, Röllig C, Showel MM, Strickland SA Jr, Vives S, Tang S, Unger TJ, Joshi A, Shen Y, Alvarez MJ, Califano A, Crochiere M, Landesman Y, Kauffman M, Shah J, Shacham S, Savona MR, Montesinos P. A 2:1 randomized, open-label, phase II study of selinexor vs. physician's choice in older patients with relapsed or refractory acute myeloid leukemia.  Leuk Lymphoma. 2021 Jul 29:1-12. doi: 10.1080/10428194.2021.1950706. Online ahead of print. PMID: 34323164
 
16. Bhatnagar B and Garzon R (2021) Clinical Applications of MicroRNAs in Acute Myeloid Leukemia: A Mini-Review. Front. Oncol. 11:679022. doi: 10.3389/fonc.2021.679022.
 
17. Bhatnagar B and Eisfeld AK.  Racial and Ethnic Survival Disparities in Patients with Hematologic Malignancies in the United States: It’s Time to Stop Ignoring the Numbers. Lancet Haematology.  2021 Dec;8(12):e947-e954. doi: 10.1016/S2352-3026(21)00303-3. PMID: 34826414
 
18. Lockwood BJ, Ntukidem OL, Ehrman SE, Schnell PM, Klemanski DL, Bhatnagar B, Lustberg M. Palliative Care Referral Patterns for Adolescent and Young Adult Patients at a Comprehensive Cancer Center. J Adolesc Young Adult Oncol. 2021 Feb;10(1):109-114. doi: 10.1089/jayao.2020.0081. Epub 2020 Jul 20. PMID: 32706607.
 
19. Buelow DR, Bhatnagar B, Orwick S, Jeon JY, Eisenmann ED, Stromatt JC, Pabla N, Blachly JS, Baker SD, Blaser BW.  BMX Kinase Mediates Gilteritinib Resistance in FLT3-mutated AML through Microenvironmental Factors. Blood Adv. 2022 Jul 7:bloodadvances.2022007952. doi: 10.1182/bloodadvances.2022007952. Online ahead of print.  PMID: 35797240
 
20. Lee S, Mohan S, Knupp J, Chamoun K, de Jonge A, Yang F, Baloglu E, Shah J, Kauffman MG, Shacham S, Bhatnagar B.  Oral eltanexor treatment of patients with higher-risk myelodysplastic syndrome refractory to hypomethylating agents. J Hematol Oncol. 2022 Aug 3;15(1):103. doi: 10.1186/s13045-022-01319-y. PMID: 35922861

Awards

Bertha A. Bouroncle Distinguished Faculty Teaching Award 2020
National Institutes of Health Loan Repayment Award 2019
Huntington Bank & Pelotonia Honor a Doctor Awards Dinner 2019
National Institutes of Health Loan Repayment Award 2017
Early Career Women Faculty Leadership Development Seminar, American Association of Medical Colleges 2017
Alliance for Clinical Trials in Oncology Young Investigator Committee 2017
Patient Satisfaction Award, FY 2016 (Top 10%

Grants and Research

Pelotonia IRP Award 2020 – 2022
TP-0903 to treat RAS mutated relapsed/refractory acute myeloid leukemia
PI: Bhavana Bhatnagar, DO & John C. Byrd, MD
Estimated budget: $25,000
DSRP Award FY20- Bhatnagar AML 46050-502807 2020
PI: Bhavana Bhatnagar, DO
Estimated budget: $50,000
Source: M2Gen Corp/H. Lee Moffitt Cancer Center 2019 – 2021
ORIEN NOVA IIP: The impact of donor gamma delta T-cell reconstitution and expression of leukemic cell ligands on immune escape and relapse of AML after allogeneic hematopoietic cell transplantation
PI: Bhavana Bhatnagar, DO
Estimated Budget: $250,000
Teen Cancer America Charitable Grant 2019 – 2021
PI: Bhavana Bhatnagar, DO
Estimated Budget: $467,540
Leukemia Research Program 2019-2020
Using Next-Generation sequencing to predict outcomes of patients with myelodysplastic syndromes and acute myeloid leukemia
PI: Bhavana Bhatnagar, DO
Estimated Budget: $37,000
Principal Investigator:
1. OSU-13182 Phase I Study of Decitabine (Dacogen) and Selinexor (KPT-330) in Acute Myeloid Leukemia
Role: Principal Investigator
Status: Closed
Sponsor: Karyopharm Therapeutics
2. OSU-14089 Phase 1 study of Selinexor in combination with Mitoxantrone, Etoposide and Cytarabine in Primary Refractory and Relapsed Acute Myeloid Leukemia
Role: Principal Investigator
Status: Open
Sponsor: Karyopharm Therapeutics
3. OSU-14169 Phase I Study of Pacritinib and Chemotherapy in Patients with Acute Myeloid Leukemia and FLT3 mutations
Role: Principal Investigator
Status: Open
Sponsor: Cell Therapeutics, Inc.
4. OSU-15258 A Phase I, Open-label, Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)
Role: Site Principal Investigator
Status: Open
Sponsor: ADC Therapeutics
Bhavana Bhatnagar, DO
Page 6 of 28
5. OSU-16127 A Phase 3 Openlabel, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation
Role: Site Principal Investigator
Status: Open
Sponsor: Astellas Pharmaceuticals
6. ECOG-E1910 A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-negative B lineage Acute Lymphoblastic Leukemia in Adults
Role: Site Principal Investigator
Status: Open
Sponsor: Eastern Cooperative Oncology Group (ECOG)
7. SWOG-S1318 A Phase II Study of Blinatumomab (NSC-765986) and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients >/= 65 Years of Age with Newly Diagnosed Philadelphia- Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib (NSC-732517), Prednisone and Blinatumomab for Patients >/= 65 Years of Age with Newly Diagnosed Philadelphia- Chromosome Positive (Ph+) ALL
Role: Site Principal Investigator
Status: Open
Sponsor: Southwest Oncology Group (SWOG)
8. OSU-16281 A Phase II Study of MLN0218 (TAK-228) in Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL)
Role: Site Principal Investigator
Status: Open
Sponsor: National Cancer Institute (NCI)
9. OSU-17214 A Multicenter, Open-label Treatment Protocol of Gilteritinib (ASP2215) in Patients with FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) with Minimal Residual Disease (MRD)
Role: Site Principal Investigator
Status: Open
Sponsor: Astellas Pharmaceuticals
10. OSU-17278 An Open-Label, Randomized, Phase II Dose-Finding Study of Pacritinib in Patients with Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis Previously Treated with Ruxolitinib
Role: Site Principal Investigator
Status: Open
Sponsor: Cell Therapeutics
11. CALGB-10403 Intergroup Phase II clinical Trial for Adolescents and young adults(<30yrs) in untreated ALL
Role: Principal Investigator
Status: Closed
Sponsor: CALGB
12. OSU-18119 A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) versus IV Decitabine in Subjects with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
Bhavana Bhatnagar, DO
Page 7 of 28
Role: Principal Investigator
Status: Closed
Sponsor: Astex
13. ALLIANCE-A041703 A Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-negative CD22-positive B-lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults with Relapsed or Refractory Disease
Role: Principal Investigator
Status: Open
Sponsor: Alliance
14. OSU-18237 Phase 1/2 Study of ASP2215 (Gilteritinib) Combined with Atezolizumab in Patients with Relapsed or Treatment Refractory FLT3 Mutated Acute Myeloid Leukemia (AML)
Role: Principal Investigator
Status: Open
Sponsor: Astellas Pharma
15. OSU-18379 A Phase II Study of TP-0903 in Combination with Chemotherapy and as Monotherapy in Patients with Acute Myeloid Leukemia and FLT3 Mutations
Role: Principal Investigator
Status: Open
Sponsor: OSU-IIT
16. ALLIANCE-A041501 A Phase III Trial To Evaluate The Efficacy Of The Addition Of Inotuzumab Ozogamicin (A Conjugated Anti-Cd22monoclonal Antibody) To Frontline Therapy In Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL
Role: Principal Investigator
Status: Open
Sponsor: Alliance
17. OSU-18140 Randomized Trial of a Collaborative Palliative and Oncology Care Model for Patients with Acute Myeloid Leukemia Role: Principal Investigator
Status: Open
Sponsor: Mass Gen
18. OSU-18185 A Phase III Randomized, Double-Blind Trial to Evaluate the Efficacy of Uproleselan Administered with Chemotherapy versus Chemotherapy Alone in Patients with Relapsed/Refractory Acute Myeloid Leukemia
Role: Principal Investigator
Status: Open
Sponsor: GlycoMimetics
19. OSU-18239 A Phase 2, Randomized, Biomarker-driven, Clinical Study in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with an Exploratory Arm in Patients with Newly Diagnosed High-Risk AML and Exploratory Arms with Varying Levels of MCL-1 Dependence
Role: Principal Investigator
Status: Open
Sponsor: Tolero
Bhavana Bhatnagar, DO
Page 8 of 28
20. OSU-16004 Mutation patterns in morphologic remission and relapse in patients with acute myeloid leukemia
Role: Principal Investigator
Status: Open
Sponsor: OSU
21. OSU-18324 A retrospective analysis on the incidence, characteristics and risk factors of venous thromboemobli (VTE) in the adolescent and young adult (AYA) acute lymphoblastic leukemia (ALL) cohort receiving pegasparaginase
Role: Principal Investigator
Status: Open
Sponsor: OSU
22. OSU-18387 A Phase Ib/II Study Evaluating the Safety and Efficacy of Idasanutlin in Combination with Cytarabine and Daunorubicin in Patients Newly Diagnosed with Acute Myeloid Leukemia (AML) and The Safety and Efficacy of Idasanutlin in the Maintenance of First AML Complete Remission
Role: Principal Investigator
Status: Open
Sponsor: F Hoffman La Roche
23. OSU-18388 The Impact of Donor #947 & #948; T-Cell Reconstitution and Expression of Leukemic Cell Ligands on Immune Escape and Relapse of AML after Allogeneic Hematopoietic Cell Transplantation
Role: Principal Investigator
Status: Open
Sponsor: OSU
24. OSU-19080 Using Next-Generation sequencing to predict outcomes of patients with myelodysplastic syndromes and acute myeloid leukemia
Role: Principal Investigator
Status: Open
Sponsor: OSU
25. OSU-19093 Assessing mechanisms of intrinsic and acquired resistance in acute myeloid leukemia patients with FLT3 mutations treated with gilteritinib
Role: Principal Investigator
Status: Open
Sponsor: OSU

Patient Care Information

Medical Specialties

  • Hematology/Oncology (Cancer)
  • Medical Oncology (Cancer)

Board Certifications

  • Hematology, American Board of Internal Medicine
  • Internal Medicine, American Board of Internal Medicine
  • Medical Oncology, American Board of Internal Medicine

Special Training

  • Fellowship, Hematology and Medical Oncology
    University of Maryland's Marlene and Stewart Greenbaum Cancer Center, Baltimore, MD, 2013
  • Residency, Internship and Residency
    The Cleveland Clinic Foundation, Cleveland, OH, 2010